ABCG1 and atherosclerosis: While our findings in vitro suggest that rHDL + T1317 combination therapy can upregulate ABCA1 and ABCG1 at the mRNA and protein level as well as increase TC efflux when compared to either drug alone, we wanted to confirm whether these findings confer a greater anti-atherosclerosis effect in vivo.